Apellis Pharmaceuticals Inc (APLS) — Capital Reinvestment Ratio

Latest as of September 2025: 0.00x

Apellis Pharmaceuticals Inc (APLS) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow ($108.47 Million) in capital expenditures ($148.00K). Check tangible net worth ratio of Apellis Pharmaceuticals Inc to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$108.47 Million
USD

Capital Expenditures

$148.00K
USD

Data as of

Sep 2025
Most recent filing

Apellis Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks Apellis Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see APLS operating cash flow.

Annual Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc from 2025 to 2025. See Apellis Pharmaceuticals Inc (APLS) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.01x $45.33 Million $313.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow